

18 April 2024

US Sales

Today we received a query from one of our North American distributors regarding our testing process for one of our previous batches. We have now identified that only twelve bags, sold in the US, have been affected by this laboratory retesting process over the last 4 ½ years.

Further to the announcement on Friday 12th April, we are trying to ascertain from our US distributors and customers the extent of the negative effect the FDA Warning Letter, regarding our OOS (Out Of Specification) procedures with respect to retesting in our laboratory, may have on US Sales and will provide further updates once we have feedback.

Authorized by:

Geoff Acton (B.Com CA)

Managing Director